Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations.
In the search for effective vaccines against intracellular pathogens such as HIV, tuberculosis and malaria, recombinant viral vectors are increasingly being used to boost previously primed T cell responses. Published data have shown prime-boost vaccination with BCG-MVA85A (modified vaccinia virus An...
Үндсэн зохиолчид: | Beveridge, N, Price, D, Casazza, J, Pathan, A, Sander, C, Asher, T, Ambrozak, DR, Precopio, M, Scheinberg, P, Alder, N, Roederer, M, Koup, R, Douek, D, Hill, A, Mcshane, H |
---|---|
Формат: | Journal article |
Хэл сонгох: | English |
Хэвлэсэн: |
2007
|
Ижил төстэй зүйлс
Ижил төстэй зүйлс
-
Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
-н: Whelan, K, зэрэг
Хэвлэсэн: (2009) -
Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.
-н: Fletcher, H, зэрэг
Хэвлэсэн: (2008) -
Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
-н: Mcshane, H, зэрэг
Хэвлэсэн: (2005) -
Polyfunctional T cell responses are a hallmark of HIV-2 infection.
-н: Duvall, MG, зэрэг
Хэвлэсэн: (2008) -
Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
-н: Kathryn T. Whelan, зэрэг
Хэвлэсэн: (2011-01-01)